AngioDynamics Shares Surge on Strong Fundamentals and Regulatory Momentum

AngioDynamics is demonstrating remarkable market momentum, driven by impressive quarterly results, favorable analyst coverage, and a significant regulatory development concerning reimbursement rates.

A pivotal development has emerged from US health authorities concerning AngioDynamics’ prostate ablation therapy. The new CPT-I code will remain within the APC-5362 category, maintaining a reimbursement rate of $10,860.07. This clarity, effective January 2026, is expected to streamline physician compensation and reduce claim denials from private insurers. Market experts at Canaccord Genuity anticipate that AngioDynamics will leverage this positive momentum throughout the entire 2026 fiscal year.

Quarterly Earnings Exceed Projections

The company’s financial performance for Q1 2026 provided a substantial boost. AngioDynamics reported net sales of $75.7 million, Read more...